Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M

Reports Q3 revenue from Caribou’s (CRBU) licensing and collaboration agreements was $3.3M for the three months ended September 30, compared to $4M for the same period in 2021. The decrease was primarily due to a decrease in revenue under the AbbVie (ABBV)collaboration and license agreement.."We have seen highly promising results from our lead allogeneic cell therapy, CB-010, at the lowest starting dose in the ANTLER clinical trial in patients with relapsed or refractory B cell non-Hodgkin lymphoma," said Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer. "The safety and antitumor activity for CB-010 at dose level 1 are encouraging, and we look forward to generating additional efficacy and durability data from the dose escalation phase of the ANTLER trial. In addition, progress continues across our pipeline as we submitted our second IND, for CB-011, in the fourth quarter and plan to submit our third IND, for CB-012, in 2023. Later this year, we look forward to sharing the target selection for CB-020, the lead program in our CAR-NK platform for solid tumors."